According to in vitro, in vivo, and clinical PCa outcomes, the main mechanisms/molecular targets of tetrahydroxycurcumin were AR pathway, NF‐kappaB, AP‐1, PI3K/Akt, Bcl‐2 family, Cyclin D, and Wnt/beta‐Catenin (Crowley et al. 2021). The gene discussed is NFKB1; the disease is posterior cortical atrophy.